Study Data from Mayo Clinic Update Understanding of Mastocytosis (Metformin: A potential adjunct for treatment of systemic mastocytosis).

A recent study conducted at the Mayo Clinic explored the potential use of metformin, an antidiabetic medication, as an adjunct treatment for systemic mastocytosis (SM). SM is a clonal disorder of mast cells that currently has no cure. The researchers investigated whether metformin, which has been shown to destroy cancer stem cells and act as a chemosensitizer, could benefit patients with both type 2 diabetes and SM. The preliminary findings suggest that early use of metformin may complement current treatments for SM by targeting cancer stem cells. [Extracted from the article]